SCHEMBL13229352

SCHEMBL13229352

Cc1ncnc(C)c1-c1ccc2c(c1)NCC2

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ JAK2 O60674 3/20 0.46
▸ JAK3 P52333 2/20 0.46
▸ S1PR1 P21453 2/20 0.45
▸ ASIC3 Q9UHC3 2/20 0.38
▸ GFER P55789 1/20 0.38
▸ SMN1; SMN2 Q16637 1/20 0.38
▸ DRD1 P21728 2/20 0.37
▸ S1PR3 Q99500 1/20 0.35
▸ DRD2 P14416 1/20 0.35
▸ DRD4 P21917 1/20 0.35
▸ PARP1 P09874 1/20 0.35
▸ PARP10 Q53GL7 1/20 0.35
▸ CDK9 P50750 1/20 0.34
▸ KDR P35968 2/20 0.34
▸ ABL1 P00519 1/20 0.33
▸ LCK P06239 1/20 0.33
▸ SYK P43405 1/20 0.33
▸ GSK3B P49841 1/20 0.33
▸ LRRK2 Q5S007 1/20 0.33
▸ BRD4 O60885 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13229320 0.90 JAK2 (0.44) JAK2JAK3S1PR1ASIC3GFER
SCHEMBL13229310 0.84 JAK2 (0.42) JAK2JAK3S1PR1ASIC3GFER
SCHEMBL17785717 0.74 JAK2 (0.41) JAK2JAK3S1PR1GFERSMN1; SMN2
SCHEMBL13229196 0.73 ASIC3 (0.40) JAK2JAK3S1PR1ASIC3GFER
SCHEMBL2685244 0.73 PDE3B (0.47) JAK2JAK3S1PR1ASIC3GFER
SCHEMBL30564582 0.71 PARP10 (0.56) S1PR1GFERSMN1; SMN2DRD2DRD4
SCHEMBL426519 0.71 PARP10 (0.56) S1PR1GFERSMN1; SMN2DRD2DRD4
SCHEMBL27993444 0.71 CD274 (0.51) GFERSMN1; SMN2PARP1PARP10
SCHEMBL24287105 0.71 BRD4 (0.53) BRD4
SCHEMBL4718616 0.70 KDM4E (0.63) S1PR1GFERSMN1; SMN2DRD2DRD4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8501747-B2 Functionally selective alpha2C adrenoreceptor agonists MERCK SHARP & DOHME CORP. (US) 2013-08-06 — — US disclosed
US-8501747-B2 Functionally selective alpha2C adrenoreceptor agonists MERCK SHARP & DOHME CORP. (US) 2013-08-06 — — US disclosed
US-20100197562-A1 FUNCTIONALLY SELECTIVE ALPHA2C ADRENORECEPTOR AGONISTS SCHERING CORPORATION AND PHARMACOPEIA, LLC (US) 2010-08-05 — — US disclosed
US-20100197562-A1 FUNCTIONALLY SELECTIVE ALPHA2C ADRENORECEPTOR AGONISTS SCHERING CORPORATION AND PHARMACOPEIA, LLC (US) 2010-08-05 — — US disclosed
WO-2008100456-A2 FUNCTIONALLY SELECTIVE ALPHA2C ADRENORECEPTOR AGONISTS SCHERING CORPORATION (US) 2008-08-21 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100197562-A1 FUNCTIONALLY SELECTIVE ALPHA2C ADRENORECEPTOR AGONISTS ADRA2C, ADRB2, ADRB3 JAK2 780/4885JAK3 2064/4885S1PR1 727/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback